CNS Oncology Publishes Tumor Treating Fields Treatment Planning and Patient Follow-up Guidelines in Glioblastoma
September 19 2016 - 7:30AM
Business Wire
Guidelines provide a framework for using the
NovoTAL System to optimize Tumor Treating Fields intensity in
Optune patients
Tumor Treating Fields extend overall survival
when combined with maintenance temozolomide in newly diagnosed
glioblastoma patients
Novocure (NASDAQ:NVCR) announced today that CNS Oncology
published Tumor Treating Fields (TTFields) treatment planning and
patient follow-up guidelines, providing a standardized resource for
the use of the NovoTAL System to optimize TTFields intensity in
Optune patients with newly diagnosed and recurrent glioblastoma
(GBM). Treatment planning with the NovoTAL System is an essential
component of treatment with TTFields. The guidelines present a
framework for utilizing the NovoTAL treatment planning software to
start patients, monitor patient response and evaluate when TTFields
treatment should be re-planned.
“Transducer array placement and TTFields intensity are important
factors in the success of treatment with Optune,” said Dr. Eilon
Kirson, Chief Science Officer and Head of Research and Development
at Novocure. “We are pleased that CNS Oncology published treatment
planning guidelines and believe the guidelines will advance Optune
as a standard treatment option in GBM.”
All glioblastoma patients starting Optune should receive
treatment planning with the NovoTAL System. In simulation studies,
personalized treatment planning with the NovoTAL system resulted in
near doubling of TTFields intensity delivered to the tumor compared
with TTFields delivered using a default symmetric array layout.
The guidelines explain that there may be a benefit to certified
physicians conducting TTFields treatment planning because they have
comprehensive information regarding the patients’ medical history,
current medical status and knowledge of sequential imaging
changes.
“The publication of TTFields treatment planning guidelines in
CNS Oncology will increase physicians’ confidence when planning
patients’ therapy with TTFields,” said Dr. John Trusheim, lead
author of the guidelines, Assistant Clinical Professor at the
University of Minnesota Medical School and Medical Director of
Neuro-oncology at the Virginia Piper Cancer Institute in
Minneapolis. “This tool will help inform physicians on how to
incorporate Optune into glioblastoma patients’ treatment,
potentially resulting in better treatment outcomes.”
Novocure’s EF-14 phase 3 pivotal trial data published
in The Journal of the American Medical Association in
December 2015 demonstrated that adding TTFields to maintenance
temozolomide significantly extended progression free and overall
survival in newly diagnosed GBM patients versus maintenance
temozolomide alone.
About Novocure
Novocure is a commercial-stage oncology company developing a
proprietary therapy called Tumor Treating Fields, or TTFields, for
the treatment of solid tumor cancers. Headquartered in Jersey,
Novocure has U.S. operations in Portsmouth, New
Hampshire, Malvern, Pennsylvania, and New York City.
Additionally, the company has offices
in Germany, Switzerland and Japan, and a
research center in Haifa, Israel. For additional information
about the company, please visit www.novocure.com or
follow us at www.twitter.com/novocure.
About Glioblastoma
Glioblastoma, also called glioblastoma multiforme, or GBM, is a
type of primary brain cancer. This means that GBM tumors begin in
the brain, rather than traveling to the brain from other parts of
the body, such as the lungs or breasts. GBM is the most common type
of primary brain cancer in adults. It is more likely to appear in
adults than children and to affect men than women.
Approved Indications
Optune is intended as a treatment for adult patients (22 years
of age or older) with histologically-confirmed glioblastoma
multiforme (GBM).
Optune with temozolomide is indicated for the treatment of adult
patients with newly diagnosed, supratentorial glioblastoma
following maximal debulking surgery and completion of radiation
therapy together with concomitant standard of care
chemotherapy.
In the United States, for the treatment of recurrent GBM, Optune
is indicated following histologically-or radiologically-confirmed
recurrence in the supratentorial region of the brain after
receiving chemotherapy. The device is intended to be used as a
monotherapy, and is intended as an alternative to standard medical
therapy for GBM after surgical and radiation options have been
exhausted.
Full prescribing information is available at
www.optune.com/safety or by calling toll free 1-855-281-9301.
Forward-Looking Statements
In addition to historical facts or statements of current
condition, this press release may contain forward-looking
statements. Forward-looking statements provide Novocure’s current
expectations or forecasts of future events. These may include
statements regarding anticipated scientific progress on its
research programs, development of potential products,
interpretation of clinical results, prospects for regulatory
approval, manufacturing development and capabilities, market
prospects for its products, and other statements regarding matters
that are not historical facts. You may identify some of these
forward-looking statements by the use of words in the statements
such as "anticipate," "estimate," "expect," "project," "intend,"
"plan," "believe" or other words and terms of similar meaning.
Novocure's performance and financial results could differ
materially from those reflected in these forward-looking statements
due to general financial, economic, regulatory and political
conditions as well as more specific risks and uncertainties facing
Novocure such as those set forth in its Annual Report on Form 10-K
filed on March 1, 2016, with the U.S. Securities and Exchange
Commission. Given these risks and uncertainties, any or all of
these forward-looking statements may prove to be incorrect.
Therefore, you should not rely on any such factors or
forward-looking statements. Furthermore, Novocure does not intend
to update publicly any forward-looking statement, except as
required by law. Any forward-looking statements herein speak only
as of the date hereof. The Private Securities Litigation Reform Act
of 1995 permits this discussion.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160919005639/en/
Media and Investor Contact:NovocureAshley Cordova,
212-767-7558acordova@novocure.com
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Mar 2024 to Apr 2024
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Apr 2023 to Apr 2024